[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002085409A3 - Methods and compositions for inducing an immune response to an antigen - Google Patents

Methods and compositions for inducing an immune response to an antigen Download PDF

Info

Publication number
WO2002085409A3
WO2002085409A3 PCT/US2001/045717 US0145717W WO02085409A3 WO 2002085409 A3 WO2002085409 A3 WO 2002085409A3 US 0145717 W US0145717 W US 0145717W WO 02085409 A3 WO02085409 A3 WO 02085409A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
antigen
inducing
immune response
Prior art date
Application number
PCT/US2001/045717
Other languages
French (fr)
Other versions
WO2002085409A2 (en
Inventor
Thomas J Schall
Dale Talbot
Robert Berkovitz
Wei Zheng
Maureen Howard
Brett Premack
Original Assignee
Chemocentryx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx filed Critical Chemocentryx
Priority to AU2002228729A priority Critical patent/AU2002228729A1/en
Publication of WO2002085409A2 publication Critical patent/WO2002085409A2/en
Publication of WO2002085409A3 publication Critical patent/WO2002085409A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).
PCT/US2001/045717 2001-04-12 2001-10-30 Methods and compositions for inducing an immune response to an antigen WO2002085409A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228729A AU2002228729A1 (en) 2001-04-12 2001-10-30 Methods and compositions for inducing an immune response to an antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83481401A 2001-04-12 2001-04-12
US09/834,814 2001-04-12

Publications (2)

Publication Number Publication Date
WO2002085409A2 WO2002085409A2 (en) 2002-10-31
WO2002085409A3 true WO2002085409A3 (en) 2002-12-27

Family

ID=25267873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045717 WO2002085409A2 (en) 2001-04-12 2001-10-30 Methods and compositions for inducing an immune response to an antigen

Country Status (2)

Country Link
AU (1) AU2002228729A1 (en)
WO (1) WO2002085409A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004282A1 (en) * 1996-07-25 1998-02-05 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells
WO1999029728A1 (en) * 1997-12-11 1999-06-17 University Of Maryland Biotechnology Institute Method and composition to enhance the efficacy of a vaccine using chemokines
EP0974357A1 (en) * 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004282A1 (en) * 1996-07-25 1998-02-05 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells
WO1999029728A1 (en) * 1997-12-11 1999-06-17 University Of Maryland Biotechnology Institute Method and composition to enhance the efficacy of a vaccine using chemokines
EP0974357A1 (en) * 1998-07-16 2000-01-26 Schering-Plough Chemokines as adjuvants of immune response
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE GIOVANNI CARLA ET AL: "The prospects for cancer gene therapy.", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 22, no. 12, December 2000 (2000-12-01), pages 1025 - 1032, XP002218907, ISSN: 0192-0561 *
GREAVES DAVID R ET AL: "Chemokines and myeloid cell recruitment.", MICROBES AND INFECTION, vol. 2, no. 3, March 2000 (2000-03-01), pages 331 - 336, XP002218908, ISSN: 1286-4579 *

Also Published As

Publication number Publication date
AU2002228729A1 (en) 2002-11-05
WO2002085409A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
WO2006036550A3 (en) Listeria-based and llo-based vaccines
BRPI0312472B8 (en) composition comprising two different iscom complexes
WO2004075829A3 (en) Adjuvanted influenza vaccine
EE05633B1 (en) Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing It, Preparation and Therapeutic Use of MVA
NO20071609L (en) Immunogenic composition for use in vaccination against staphylococci
EP1659178A3 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP1246644A4 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
WO2004026265A3 (en) Compositions and methods for treatment of herpesvirus infections
MXPA01007760A (en) Immunological adjuvant compound.
BR0211296A (en) Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2004073319A8 (en) Methods and compounds for raising antibodies and for screening antibody repertoires
WO2006105993A3 (en) Method for shielding functional sites or epitopes on proteins
CA2272338A1 (en) Immunization of infants
WO2005007673A3 (en) Immunogenic peptides
MY125000A (en) Novel compositions
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP